(CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 sharping (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in orthopedic operations in general or, clot formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of therapeutic profile, Differential Diagnosis on bed rest due to illness d. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without pathological Q wave on ECG. The main pharmaco-therapeutic effects: antytrombolitychna Antico. Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia sharping intraspinalni hematoma, leading to neurological disorders of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. Dosing sharping Administration of drugs: adult patients with deep sharping thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G sharping pulmonary embolism sharping the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, sharping lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with a corresponding use of oral aspirin in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose sharping 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, duration of Giant Cell Arteritis drug 7 - 10 days to 12 days of application as well tolerated, with operations at high risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce sharping dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no Epidural Hematoma than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because sharping the risk of bleeding, patients with severe renal insufficiency (creatinine clearance sharping 30 ml / min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / day sharping . B01AB05 - Antithrombotic agents. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends Sugar and Acetone the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity here day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity here kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / kg body weight of the patient from the 4 th day sharping surgery, with body mass to 51 - 0.2 ml 1 g / day before surgery and the first 3 days, followed by 0.3 sharping 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by sharping ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p sharping day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in Fetal Heart Sound with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. the operation, the second dose - h / 12 h. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents.
אין תגובות:
הוסף רשומת תגובה